175 related articles for article (PubMed ID: 11697498)
1. Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma.
Avigdor A; Raanani P; Levi I; Hardan I; Ben-Bassat I
Leuk Lymphoma; 2001 Aug; 42(4):683-7. PubMed ID: 11697498
[TBL] [Abstract][Full Text] [Related]
2. Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
del Giglio A; Weinschenker P; Manhani AR; Carbonell AL; Mitteldorf CA
South Med J; 2005 Feb; 98(2):238-40. PubMed ID: 15759959
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas.
Bladé J; Perales M; Rosiñol L; Tuset M; Montoto S; Esteve J; Cobo F; Villela L; Rafel M; Nomdedeu B; Montserrat E
Br J Haematol; 2001 May; 113(2):422-4. PubMed ID: 11380408
[TBL] [Abstract][Full Text] [Related]
4. Extramedullary multiple myeloma escapes the effect of thalidomide.
Rosiñol L; Cibeira MT; Bladé J; Esteve J; Aymerich M; Rozman M; Segarra M; Cid MC; Filella X; Montserrat E
Haematologica; 2004 Jul; 89(7):832-6. PubMed ID: 15257935
[TBL] [Abstract][Full Text] [Related]
5. Association between intracranial plasmacytoma and multiple myeloma: clinicopathological outcome study.
Schwartz TH; Rhiew R; Isaacson SR; Orazi A; Bruce JN
Neurosurgery; 2001 Nov; 49(5):1039-44; discussion 1044-5. PubMed ID: 11846895
[TBL] [Abstract][Full Text] [Related]
6. Discordant response or progression in patients with myeloma treated with thalidomide-based regimens.
Anagnostopoulos A; Hamilos G; Zorzou MP; Grigoraki V; Anagnostou D; Dimopoulos MA
Leuk Lymphoma; 2004 Jan; 45(1):113-6. PubMed ID: 15061206
[TBL] [Abstract][Full Text] [Related]
7. A case of extramedullary plasmablastic plasmacytoma successfully treated using a combination of thalidomide and dexamethasone and a review of the medical literature.
Sekiguchi Y; Asahina T; Shimada A; Imai H; Wakabayashi M; Sugimoto K; Nakamura N; Sawada T; Komatsu N; Noguchi M
J Clin Exp Hematop; 2013; 53(1):21-8. PubMed ID: 23801130
[TBL] [Abstract][Full Text] [Related]
8. Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma.
Terpos E; Rezvani K; Basu S; Milne AE; Rose PE; Scott GL; Rahemtulla A; Samson D; Apperley JF
Eur J Haematol; 2005 Nov; 75(5):376-83. PubMed ID: 16191086
[TBL] [Abstract][Full Text] [Related]
9. [Plasmocytoma in the nasal cavity and paranasal sinuses].
Bień S; Kobiorska-Nowak J
Otolaryngol Pol; 2009; 63(3):287-92. PubMed ID: 19886539
[TBL] [Abstract][Full Text] [Related]
10. [A clinical analysis of 25 cases of multiple myeloma complicated by extramedullary plasmacytomas].
Zhong YP; Chen SL
Zhonghua Nei Ke Za Zhi; 2009 May; 48(5):396-8. PubMed ID: 19615158
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?
Marchica V; Accardi F; Storti P; Mancini C; Martella E; Dalla Palma B; Bolzoni M; Todoerti K; Marcatti M; Schifano C; Bonomini S; Sammarelli G; Neri A; Ponzoni M; Aversa F; Giuliani N
Int J Hematol; 2017 Jan; 105(1):104-108. PubMed ID: 27699576
[TBL] [Abstract][Full Text] [Related]
12. Progressive myeloma after thalidomide therapy in a patient with immature phenotype of myeloma (plasma) cells.
Okikawa Y; Sakai A; Takimoto Y; Noda M; Imagawa J; Katayama Y; Kuroda Y; Okita H; Fujimura K; Kimura A
Int J Hematol; 2004 May; 79(4):364-8. PubMed ID: 15218967
[TBL] [Abstract][Full Text] [Related]
13. Primary extramedullary plasmacytoma with diffuse lymph node involvement: a case report and review of the literature.
Naymagon L; Abdul-Hay M
J Med Case Rep; 2019 May; 13(1):153. PubMed ID: 31113466
[TBL] [Abstract][Full Text] [Related]
14. Extramedullary Manifestation of Multiple Myeloma in the Oral Cavity.
de Assis Pereira Hansen C; Filho JS; de Mattos Nascimento M; Alves FA; Neotti T; D Almeida Costa F
Arch Iran Med; 2018 Dec; 21(12):611-612. PubMed ID: 30634861
[TBL] [Abstract][Full Text] [Related]
15. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach.
Bladé J; Fernández de Larrea C; Rosiñol L; Cibeira MT; Jiménez R; Powles R
J Clin Oncol; 2011 Oct; 29(28):3805-12. PubMed ID: 21900099
[TBL] [Abstract][Full Text] [Related]
16. Recurrent multiple myeloma presenting as a breast plasmacytoma.
Kalyani A; Rohaizak M; Cheong SK; Nor Aini U; Balasundaram V; Norlia A
Med J Malaysia; 2010 Sep; 65(3):227-8. PubMed ID: 21939175
[TBL] [Abstract][Full Text] [Related]
17. Clinical profile of multiple myeloma and effect of thalidomide based treatment on its outcome.
Sridhar S; Dutta TK; Basu D
J Indian Med Assoc; 2011 Dec; 109(12):880-2, 887-8. PubMed ID: 23469567
[TBL] [Abstract][Full Text] [Related]
18. Cranial nerve palsy in multiple myeloma and solitary plasmacytoma.
Kashyap R; Kumar R; Kumar S
Asia Pac J Clin Oncol; 2010 Dec; 6(4):251-5. PubMed ID: 21114773
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of thalidomide in refractory multiple myeloma.
Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeddis J; Barlogie B
N Engl J Med; 1999 Nov; 341(21):1565-71. PubMed ID: 10564685
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
